---
title: "Trinity Biotech plc (TRIB.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TRIB.US.md"
symbol: "TRIB.US"
name: "Trinity Biotech plc"
industry: "Health Care Equipment"
datetime: "2026-05-20T11:27:01.755Z"
locales:
  - [en](https://longbridge.com/en/quote/TRIB.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TRIB.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TRIB.US.md)
---

# Trinity Biotech plc (TRIB.US)

## Company Overview

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren’s syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia.

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Exchange | US Market |
| Website | [www.trinitybiotech.com](https://www.trinitybiotech.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: D (0.68)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 146 / 183 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -28.87% |  |
| Net Profit YoY | -17.58% |  |
| P/B Ratio | -0.15 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 10573208.61 |  |
| Revenue | 43785000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 69.76% | A |
| Profit Margin | -85.36% | E |
| Gross Margin | 38.57% | B |
| Revenue YoY | -28.87% | E |
| Net Profit YoY | -17.58% | D |
| Total Assets YoY | 1.82% | C |
| Net Assets YoY | -104.60% | E |
| Cash Flow Margin | 15.86% | D |
| OCF YoY | -28.87% | E |
| Turnover | 0.42 | C |
| Gearing Ratio | 168.45% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Trinity Biotech plc",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-28.87%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-17.58%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-0.15",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "10573208.61",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "43785000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "69.76%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-85.36%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "38.57%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-28.87%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-17.58%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "1.82%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "-104.60%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "15.86%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-28.87%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.42",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "168.45%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.28 | 68/183 | - | - | - |
| PB | -0.15 | 152/183 | - | - | - |
| PS (TTM) | 0.24 | 6/183 | 0.30 | 0.26 | 0.20 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Delcath (DCTH.US) | C | A | B | A | A | A |
| 02 | Electromed (ELMD.US) | A | B | A | A | B | A |
| 03 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B |
| 04 | Stryker (SYK.US) | A | C | C | C | B | B |
| 05 | Boston Scientific (BSX.US) | A | B | C | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2025-06-11T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.57 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/TRIB.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/TRIB.US/norm.md)
- [Related News](https://longbridge.com/en/quote/TRIB.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/TRIB.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**